Immediate Impact
2 by Nobel laureates 72 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Screening for Breast Cancer
2024 Standout
Works of Rhonda Aoki being referenced
Individual‐ and neighborhood‐level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California
2021
A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers.
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Rhonda Aoki | 27 | 13 | 2 | 22 | 10 | 62 | |
| Özlem Özkul | 29 | 7 | 13 | 12 | 73 | ||
| Catalona Wj | 24 | 23 | 25 | 9 | 69 | ||
| Monica Yang | 29 | 10 | 18 | 12 | 81 | ||
| C. Owen | 41 | 16 | 28 | 9 | 71 | ||
| A. Arias | 19 | 24 | 21 | 10 | 82 | ||
| Mirjam Fechter | 27 | 20 | 12 | 15 | 166 | ||
| Hanadi Rafii | 14 | 13 | 22 | 15 | 73 | ||
| Coline HM van Moorsel | 13 | 25 | 9 | 9 | 85 | ||
| �. Larsson | 18 | 11 | 12 | 10 | 53 | ||
| Olamide Olawoyin | 27 | 27 | 23 | 9 | 89 |
All Works
Login with ORCID to disown or claim papers
Loading papers...